Main Uses of Jivi

Jivi is a recombinant DNA-derived coagulation factor VIII concentrate indicated for use in adults and adolescents aged 12 years and older who have hemophilia A (congenital factor VIII deficiency).

In individuals with hemophilia A, the blood does not clot normally because of a lack of functional factor VIII protein. Jivi works by temporarily replacing the missing factor VIII, which helps the blood to clot and prevents or stops bleeding episodes.

Therapeutic Applications

The medication is utilized for several clinical purposes in the management of hemophilia A:

• On-demand Treatment: Used to control and stop bleeding episodes when they occur.
• Perioperative Management: Used to manage and prevent bleeding during and after surgical procedures.
• Routine Prophylaxis: Administered on a regular schedule to reduce the frequency of spontaneous bleeding episodes.

Clinical Benefits

Factor VIII Level Maintenance

Jivi is a PEGylated protein, meaning it has been modified to stay in the bloodstream longer than standard factor VIII products. This extended half-life allows for maintained levels of factor VIII in the plasma for longer periods, which can help protect against bleeds between administrations.

Prevention of Joint Damage

By reducing the frequency of bleeding episodes through routine prophylaxis, Jivi helps prevent long-term complications associated with hemophilia A. Frequent bleeding into joints (hemarthrosis) can lead to chronic pain and permanent joint damage; consistent prevention of these bleeds is a primary goal in maintaining mobility and long-term joint health.

Support During Surgery

For patients undergoing elective or emergency surgery, the medication provides the necessary coagulation support to allow for safe surgical intervention and recovery, mimicking the clotting capabilities of individuals without a factor VIII deficiency.

The official regulatory documents define strict eligibility criteria for the use of Jivi (damoctocog alfa pegol). The medicine is indicated for use only in previously treated patients (PTPs) with Haemophilia A (congenital Factor VIII deficiency) who are 7 years of age and older.

Absolute Contraindications

Use is absolutely prohibited (contraindicated) for any patient who has a history of hypersensitivity or severe allergic reactions to:

• Damoctocog alfa pegol (the active substance).
• Polyethylene glycol (PEG), a key component of the medicine.
• Mouse or hamster proteins, which may be present as trace manufacturing residues.

Age and Use Restrictions

The medicine is not indicated for several specific populations, including:

• Children under 7 years of age, due to a greater labeled risk for hypersensitivity reactions and/or loss of effectiveness.
• Previously untreated patients (PUPs).
• Patients with von Willebrand disease.

Conditional Use: Patients must be monitored for the development of Factor VIII neutralizing antibodies (inhibitors) or anti-PEG antibodies, as the emergence of these antibodies can severely limit the medicine's effectiveness.

Interactions with other medicines and products

Official regulatory documentation defines the interaction profile of Jivi (damoctocog alfa pegol) primarily by the absence of conventional pharmacokinetic drug-drug interactions.

As a large recombinant protein, the medication is cleared by proteolytic degradation, meaning regulatory labels do not report formal interactions involving Cytochrome P450 (CYP) enzymes or drug transporters.

---

Documented Pharmacodynamic and Procedural Constraints

The regulatory profile does, however, include specific pharmacodynamic constraints and restrictions:

• Antifibrinolytic Agents: Co-administration with antifibrinolytic medicines (such as aminocaproic acid) is associated with an increased risk or severity of thrombotic events, which is a documented pharmacodynamic interaction due to additive effects on the clotting process.
• Assay Interference: Factor VIII activity in the blood must be monitored using a validated chromogenic substrate assay or a validated one-stage clotting assay. This procedural constraint is necessary because the presence of the medication may affect the results of non-validated clotting assays.

Contraindication

The most significant interaction-related restriction is a formal contraindication for patients with a known history of hypersensitivity to the active substance or to mouse or hamster proteins, as trace amounts from the manufacturing process may be present.

Factor VIII Replacement and Intrinsic Cascade Activation

Jivi (damoctocog alfa pegol) is a recombinant, PEGylated human coagulation factor VIII ( rFVIII) molecule that functions as a plasma Factor VIII replacement. It enters the intrinsic coagulation cascade by forming a complex with activated Factor IX ( FIXa). This resulting Factor IXa/ VIIIa complex then serves as a critical enzyme complex, catalyzing the conversion of Factor X ( FX) into its activated form, Factor Xa ( FXa). This activation of the downstream cascade promotes fibrin clot formation.

---

PEGylation-Mediated Clearance Modification

The Factor VIII molecule in Jivi is site-specifically conjugated with a single 60-kDa branched polyethylene glycol ( PEG) moiety. This chemical modification prolongs the molecule's plasma half-life by modulating the interaction between Factor VIII and its physiological clearance receptors. This process engages mechanisms that regulate the compound's removal from circulation, resulting in sustained Factor VIII plasma levels.

Administration Overview

Jivi is administered via intravenous injection. The process involves preparing the powder medication with a provided diluent and using a sterile administration set.

Preparation and Reconstitution

Before administration, the medication must be reconstituted. This involves transferring the liquid diluent into the vial containing the lyophilized powder. The following general principles apply to the preparation process:

• Temperature: The medication should typically be at room temperature before the reconstitution process begins.
• Inspection: Once the powder is dissolved, the solution should be clear and colorless. If the solution is cloudy or contains visible particles, it should not be used.
• Handling: The vial should be swirled gently to dissolve the powder. Shaking the vial vigorously can damage the proteins in the medication.

Intravenous Injection

After the solution is prepared, it is drawn into a syringe for injection into a vein. The rate of administration is generally determined by the comfort level of the individual, though a slow infusion is standard practice.

Self-Administration

Individuals may be trained by healthcare professionals to perform the infusion at home. This training covers the identification of appropriate veins, sterile technique, and the proper disposal of needles and equipment.

Treatment Schedule

The frequency of administration is based on the individual’s clinical needs, including the severity of the factor VIII deficiency and the specific goal of treatment, such as routine prophylaxis to prevent bleeding episodes or on-demand treatment for active bleeds.

Research Evidence / Overview of Studies for Jivi

The clinical evidence for Jivi (damoctocog alfa pegol) is primarily drawn from a comprehensive research program, including the main PROTECT VIII pivotal trial and long-term follow-up studies. This research examined the use of the medicine across three key areas: routine bleed prevention, acute bleed management, and surgical support. Major health authorities reviewed the evidence base to determine the scope of use, while regulatory documents describe areas of study and remaining uncertainty.

---

Evidence for Routine Prevention of Bleeding Episodes

The main body of evidence comes from open-label trials that were used in research exploring how bleeding patterns change over time when Jivi is used regularly. Researchers primarily studied previously treated males (PTPs) with severe Hemophilia A. The core outcome measured in these studies was the Annualized Bleeding Rate (ABR).

Research focused on different dosing schedules to examine patterns related to bleed frequency and to investigate the influence of the extended-duration design. Studies reported sustained measurements of low ABRs across the observed patient populations. These findings describe patterns observed in the studies. Follow-up studies, which tracked patients for several years, reported how bleeding frequencies evolved over the observation period.

---

Evidence for Managing Acute Bleeding Events

Jivi was studied for the treatment of acute, spontaneous, or traumatic bleeding events as they occurred. The studies monitored outcomes related to functional imbalance by assessing the level of hemostatic control (how well the clotting process stabilized) achieved for each event. Reports described patterns observed in the studies where investigators assessed hemostatic control for acute bleeding events.

---

Key Limitations and Remaining Research Gaps

Research provides context but not individual predictions, and study findings describe patterns observed so far—and what is still uncertain. Key limitations include the open-label trial design, meaning comparative evidence is lacking against a randomized Factor VIII control for the main outcome. Furthermore, data for certain groups remain insufficient, particularly previously untreated patients (PUPs). Evidence for children under 7 years of age is limited, and this age group was largely excluded from research.

Common questions about Jivi (FAQ)

Q: How quickly can I expect Jivi to start working after administration?

Factor VIII activity levels in the blood are measurable immediately following the infusion. Dosing calculations are based on the empirical finding that one International Unit per kilogram body weight is expected to increase the Factor VIII level in the blood by approximately 1.5% to 2.5% of normal activity.

Q: What is the expected duration of the effect of Jivi after each infusion?

Jivi is an extended half-life (EHL) treatment, which means the active ingredient is designed to stay in the bloodstream for a longer period than traditional products. Official pharmacokinetic studies in adults and adolescents show the median terminal half-life (t1/2) is approximately 17 to 18 hours. This pharmacological feature is described in official documents as supporting extended dosing intervals.

Q: Can Jivi cause allergic reactions, and what are the symptoms?

Hypersensitivity, or allergic reactions, are listed as common in official safety information, with severe reactions (anaphylaxis) also being a possibility. Early symptoms may include chest or throat tightness, dizziness, low blood pressure, or nausea. These signs may indicate a serious reaction, and a healthcare provider should be contacted.

Q: Are there any known food or drink restrictions while using Jivi?

Official regulatory documents do not report formal pharmacokinetic interactions with conventional food or drinks. The medicine is primarily cleared by proteolytic degradation, meaning it is not generally expected to interact with food or drinks through common metabolic pathways.

Q: Can Jivi be used in people with hemophilia A who have pre-existing conditions?

Official regulatory documents do not specify restrictions related to most chronic pre-existing conditions. Use is formally contraindicated (prohibited) only for patients with a known history of severe allergic reactions to the active substance, polyethylene glycol (PEG), or trace amounts of mouse or hamster proteins.

Q: Is Jivi treatment suitable for pregnant or breastfeeding individuals?

There are no adequate and well-controlled studies of Jivi use in pregnant women, and the potential for causing harm to a fetus is unknown. Official documents state that it is for use during pregnancy only when the potential benefit is considered to justify the potential risk. It is also not known whether the medicine passes into human milk during breastfeeding.

Q: What should I do if my regular infusion schedule for Jivi is disrupted?

If a regular prophylactic dose is missed, regulatory guidance suggests administering the dose as soon as possible, then continuing with the regular schedule. Separately, once the medicine is prepared, the reconstituted solution is subject to a stability limitation and should be used within three hours.

Q: Is it normal to feel a mild burning sensation during the Jivi infusion?

Official safety information lists injection site reactions as a common adverse reaction. Hypersensitivity reactions can sometimes include symptoms like stinging or a burning sensation at the infusion site. Discomfort during infusion should be discussed with a healthcare provider.

Q: What if I need emergency surgery—will Jivi be enough to manage bleeding?

Jivi is formally indicated for the perioperative management of bleeding, including major surgery. The medicine is used as a component in managing bleeding to achieve and maintain required Factor VIII activity levels (e.g., 80–100 IU/dL) during the time of surgery and recovery.

Q: What is the process for monitoring my health while using Jivi?

Patients are monitored for the formation of Factor VIII neutralizing antibodies (inhibitors) using appropriate laboratory tests and clinical observations. Additionally, Factor VIII activity levels in the blood should be regularly monitored to confirm the medicine is functioning as expected.

Q: Does Jivi affect the results of routine blood tests?

Jivi may affect the results of certain clotting assays. To accurately measure the Factor VIII activity in the blood, testing should be done using a validated chromogenic assay or a validated one-stage clotting assay, as non-validated tests may inaccurately report the factor level.

Q: Does Jivi have a different factor recovery rate than other products?

The expected incremental recovery (IR) is a measurable parameter described in regulatory documents. Official information states that one International Unit per kilogram of body weight is expected to raise the Factor VIII level by approximately 2 IU/dL. This rate is a key pharmacokinetic feature of the medicine.

Q: How does Jivi differ from other factor VIII products used for hemophilia A?

Jivi is categorized as a recombinant, PEGylated human coagulation factor VIII concentrate. The PEGylation (attachment of a polyethylene glycol molecule) is a chemical modification. This modification is described in official documents as prolonging the Factor VIII's presence in the bloodstream, compared to non-PEGylated products.

Q: What are the most commonly reported side effects of Jivi?

In clinical trials, the most commonly reported side effects (incidence ge 5%) were headache, fever (pyrexia), cough, and abdominal pain. The full safety profile, including frequency classifications, is detailed in the official regulatory documents.

Q: Is it possible to develop an inhibitor while using Jivi?

The formation of neutralizing antibodies, known as inhibitors, against Factor VIII is a recognized risk for all Factor VIII products and has been reported in clinical studies. Patients are monitored regularly to detect inhibitor formation, as it can severely limit treatment effectiveness.

Q: Can Jivi be taken alongside other medications for related health issues?

Regulatory documents specifically state that co-administration with antifibrinolytic agents (medicines used to prevent the breakdown of clots) is associated with a reported increased risk or severity of thrombotic events. No other formal drug-drug interactions involving its clearance mechanism are reported.

Q: What is the risk of viral transmission with Jivi?

Jivi is a recombinant DNA-derived product, meaning the active Factor VIII protein is produced in a controlled laboratory setting and is not derived from human blood plasma. As a result, the risk of transmitting viruses carried in human blood is considered to be eliminated.

Q: Why do some people with hemophilia A choose Jivi over other options?

Jivi is distinguished by its PEGylated extended half-life (EHL) design. This pharmacological feature is a key consideration that supports extended intervals between preventative infusions, which may be relevant to an individual's treatment plan.

Q: Does Jivi contain any ingredients that could be relevant for dietary restrictions?

The lyophilized (freeze-dried) powder contains excipients (non-active ingredients) including sucrose, histidine, glycine, sodium chloride, and calcium chloride dihydrate. Patients should review the full list of ingredients with a healthcare provider if they have specific dietary concerns.

Q: Is Jivi considered an 'on-demand' or a preventative treatment?

According to official regulatory indications, Jivi is approved for use in both contexts. It is indicated for routine prophylaxis (preventative treatment) to reduce bleeding frequency, and it is also indicated for the on-demand treatment and control of acute bleeding episodes.

Q: What research is currently underway for Jivi (post-approval studies)?

Official regulatory documents, such as the European Medicines Agency’s Risk Management Plan, mention ongoing post-authorization studies. These are often conducted to further investigate the medicine’s long-term safety in real-world settings and to assess the potential for accumulation of the polyethylene glycol (PEG) component.

Q: How can I know if Jivi is actually working to prevent my bleeds?

The effectiveness of the preventative use of this medicine is assessed clinically by monitoring the Annualized Bleeding Rate (ABR). Maintaining a consistently low ABR is the key measure used in studies and by healthcare providers to assess the medicine’s long-term success in reducing the frequency of bleeding episodes.

Q: Is the dosing frequency of Jivi personalized based on patient weight?

Yes, the required dose for Jivi is calculated individually. Official dosing and administration instructions state that standard dosages are expressed in International Units per kilogram (IU/kg) of the patient's body weight.

Q: Will I need to change my Jivi treatment if I travel to a different climate?

While the unopened vials are typically stored in a refrigerator, regulatory documents permit the product to be stored for a single, continuous period of up to 6 months at room temperature (not to exceed 25 C or 30 C, depending on the region). Regulatory documents require the date of removal from refrigeration to be recorded on the carton.

Jivi (damoctocog alfa pegol) requires specific environmental conditions to maintain stability, as required by regulatory labeling.

Storage Requirements

The unopened powder and solvent vials must be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). The product must not be frozen and should be kept in its original carton to protect it from light.

Regulatory documents permit the product to be stored for a single, continuous period of up to 6 months at room temperature (not exceeding 25°C or 30°C). If this is done, the date of removal from refrigeration must be recorded on the carton, and the product must not be returned to the refrigerator.

Stability and Disposal

Once the solution is reconstituted, it must be used within 3 hours. Any unused portion is for single use only and must be discarded. The medicine must be kept out of the sight and reach of children.

Disposal must avoid wastewater and household waste. Used needles and syringes must be placed immediately into a designated puncture-proof sharps container.